



PRESS RELEASE

Published: 28-06-2023

Inhalation Sciences wins new Purchase Order from Asian distributor worth 94,000 USD

Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, the second order from the region in a week. The order includes *in vitro* modules for inhaled drug development.

ISAB has received a new order for its *in vitro* technology from a regional distributor in Asia worth 94,000 USD. It is the second order from the region in one week.

Investment and innovation in inhaled therapies has increased significantly in Asia-Pacific over recent years. In September 2022, for example, China approved the world's first inhaled Covid-19 vaccine for emergency use (1).

The advantages of *in vitro* testing in inhalation drug development are becoming increasingly understood and prioritized in the industry. *In vitro* dissolution testing that can for example generate predictive IVIVC (*in vitro in vivo* correlated) data early on, can significantly reduce risks and costs, accelerating the development of both novel and inhaled generics. ISAB has two different *in vitro* testing systems in its product portfolio.

CEO Manoush Masarrat: "We have been working closely with our local distributors over a long time now and I am delighted to see a second order from the Asian market. We look forward to see our technology play a part in developing vital new therapies in this dynamic region."

(1) CNN - <https://edition.cnn.com/2022/09/06/china/china-covid-19-vaccine-cansino-intl-hnk/index.html>

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 28 June 2023.